New Delhi, 24 June (IANS). A study by the Indian Council of Medical Research found that in the treatment of Hemophilia A (Genetic Bleeding Disorder), a low dose drug drug amiciazumab can be as effective as standard doses.
This drug prevents or reduces bleeding by mimicking blood -decreased clotting factor VIII.
According to official government data, 27,000 hemophilia patients are registered in India and it is estimated that 1,40,000 people may be affected.
ICMR’s study revealed that low -dose ecizimab may be an alternative to affordable treatment for Hemophilia A patients in developing countries. The standard dose is priced at around $ 15,000 (about 12.5 lakh rupees), which is expensive for the economically weaker section.
“We tried to understand the effectiveness of low dosage in this study,” said Dr. Manisha Madkiyer, Director of ICMR-Nagpur Center for Research Management and Control of Hemoglobinopathy, said, as the high dose costs it out of reach of many people. “
He said that the cost of treatment with low doses will be less than 50 percent, which can save more than Rs 7 crore for a lifetime treatment for the average age of 50 years and a patient weighing 50 kg.
In the study, the emirates of low dose ecosyzumab were compared to the low -dose factor VIII profilexis.
According to the study published in the Journal of Thrombosis and Hemostasis, the cost of an amicizomab of a low dose was around $ 6,000 (about Rs 5 lakh), while the low -dose recombinant FVIIII Propilaxis cost $ 6,282 (the cost of whose type of factor was $ 3,432 to $ 7,920).
Dr. Manisha Madkikar said, “We proved that the low dose is equally effective in the treatment of amicizomab hemophilia.”
Hemophilia can cause damage to joints and bleeding in 80 percent of cases, especially in knees, ankles, elbows and hips. Emiresiazumab of low doses helps prevent bleeding, improving the health of the joints and increasing the life quality of patients. This drug provides better protection.
-IANS
MT/GKT
